Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
Ilaria Attili, Antonio Passaro, Carla Corvaja, et al.
Cancer Treatment Reviews (2023) Vol. 119, pp. 102602-102602
Closed Access | Times Cited: 19

Showing 19 citing articles:

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 34, pp. 4029-4039
Closed Access | Times Cited: 47
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
Alessandra Ferro, G.M. Marinato, C. Mulargiu, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104295-104295
Open Access | Times Cited: 23
EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47
Liyang Hu, Weitao Zhuang, Mao-jian Chen, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 8, pp. 1186-1200
Closed Access | Times Cited: 18
Oncogenic Mutations and the Tumor Microenvironment: Drivers of Non-Small Cell Lung Cancer Progression
Achilleas Mitrakas, Christos Kakouratos, Ioannis Lamprou, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 853-853
Open Access
The role of chemoradiotherapy and immunotherapy in stage III NSCLC
Zsuzsanna Orosz, Árṕad Kov́acs
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 3
The role of immunotherapy in early-stage and metastatic NSCLC
Attila Lieber, Attila Makai, Zsuzsanna Orosz, et al.
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 3
Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT)
Cesare Gridelli, Tony Mok, Pasi A. Jänne, et al.
Lung Cancer (2025) Vol. 201, pp. 108100-108100
Closed Access
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting
Filippo de Marinis, Andrea Ardizzoni, Ilaria Attili, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 110-110
Open Access
Clinical outcomes of EGFR-TKI in advanced lung squamous cell carcinoma and EGFR-TKI remodel tumor immune microenvironment
Zhuo Chen, J. Gong, Jing Chen, et al.
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access
The Decrease of PD-L1 Expression Affects the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Lung Squamous Cell Carcinoma
Jie Yin, Du Mingzhan, Gong Yinhua, et al.
American Journal of Therapeutics (2025)
Closed Access
Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR‐TKI Treatment: A Retrospective Cohort Study
Yanjun Su, Shu‐Farn Tey, Chung‐Ta Lee, et al.
The Kaohsiung Journal of Medical Sciences (2025)
Open Access
The role of PD-L1 in patients with non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy: a meta-analysis
Dun‐Chang Mo, Jianfeng Huang, Peng Lin, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations
Marcus Rathbone, Conor O’Hagan, Helen Wong, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1249-1249
Open Access | Times Cited: 1
Durable Response of Pembrolizmab for <i>EGFR</i> Mutation-positive Lung Adenocarcinoma with Early Progression to Osimertinib in First-line Treatment
Aoi Miyazaki, Koichi Saruwatari, Toru Yamanaka, et al.
Internal Medicine (2024)
Open Access | Times Cited: 1
Response to Commentary on “EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47”
Weitao Zhuang, Liyang Hu, Wenfeng Fang
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 10, pp. e50-e51
Closed Access | Times Cited: 1
Efficacy and safety of osimertinib plus bevacizumab versus osimertinib alone for advanced non–small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials
Yao Ling, Chunzhen Zhang, Dailong Li, et al.
Medicine (2024) Vol. 103, Iss. 45, pp. e40320-e40320
Open Access | Times Cited: 1
Proceedings of the 1st biannual bridging the gaps in lung cancer conference
Narjust Florez, Sandip Pravin Patel, Heather A. Wakelee, et al.
The Oncologist (2024)
Open Access
Stereotactic ablative radiotherapy and immunotherapy for early-stage lung cancer
Elif Hindié
The Lancet (2024) Vol. 404, Iss. 10449, pp. 241-241
Closed Access
Editorial: Advances in the use of EGFR TKIs in the treatment of NSCLC
Paola Ulivi
Frontiers in Oncology (2024) Vol. 14
Open Access
Page 1

Scroll to top